Provided by Tiger Fintech (Singapore) Pte. Ltd.

Orchestra BioMed

3.03
+0.11003.77%
Post-market: 2.97-0.0600-1.98%19:50 EDT
Volume:134.98K
Turnover:401.73K
Market Cap:116.09M
PE:-1.71
High:3.08
Open:2.91
Low:2.89
Close:2.92
Loading ...

Director Eric S. Fain Reports Disposal of Common Shares of Orchestra Biomed Holdings Inc

Reuters
·
28 Jun

Orchestra Biomed Holdings Inc. Conducted Annual Stockholders Meeting

Reuters
·
25 Jun

Orchestra BioMed Holdings Inc. to Present AVIM Therapy Insights at CSI 2025 Meeting

Reuters
·
18 Jun

B. Riley Cuts Price Target on Orchestra BioMed Holdings to $12 From $15, Keeps Buy Rating

MT Newswires Live
·
30 May

Promising Innovations and Strategic Advancements Drive Buy Rating for Orchestra BioMed Holdings

TIPRANKS
·
17 May

Orchestra BioMed Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
14 May

Orchestra BioMed Hldgs Q1 EPS $(0.49) Misses $(0.48) Estimate, Sales $868.00K Beat $575.80K Estimate

Benzinga
·
13 May

Orchestra BioMed reports Q1 EPS (49c), consensus (48c)

TIPRANKS
·
13 May

Orchestra BioMed Holdings Reports Q1 2025 Revenue Increase to $0.9M, Net Loss Widens to $18.8M, EPS at $0.49 Loss

Reuters
·
13 May

Orchestra Biomed Q1 EPS USD -0.49 VS. Ibes Estimate USD -0.48

THOMSON REUTERS
·
13 May

Press Release: Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Dow Jones
·
13 May

Orchestra BioMed Holdings Is Maintained at Overweight by Barclays

Dow Jones
·
06 May

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
05 May

Major Shareholder Boosts Investment in Orchestra BioMed Holdings!

TIPRANKS
·
30 Apr

Orchestra BioMed Receives US FDA Approval for Heart Device Trial

MT Newswires Live
·
30 Apr

BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon

Reuters
·
29 Apr

Orchestra Biomed Holdings Inc: Targeting Initiation of Virtue Trial During Second Half of 2025

THOMSON REUTERS
·
29 Apr

Orchestra Biomed Receives FDA Approval of Ide to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-Angioinfusion Balloon, Virtue SAB, Head-to-Head With Paclitaxel-Coated Balloon

THOMSON REUTERS
·
29 Apr

Orchestra BioMed Holdings: Buy Rating Affirmed on Breakthrough Device Designation and Promising AVIM Therapy Developments

TIPRANKS
·
24 Apr

Orchestra BioMed granted breakthrough device designation, says H.C. Wainwright

TIPRANKS
·
24 Apr